X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1472) 1472
oncology (1014) 1014
index medicus (890) 890
female (783) 783
male (677) 677
middle aged (656) 656
aged (563) 563
adult (529) 529
cancer (520) 520
chemotherapy (401) 401
treatment outcome (355) 355
antineoplastic combined chemotherapy protocols - therapeutic use (343) 343
phase-i/ii (293) 293
radiotherapy (278) 278
phase i/ii (268) 268
care and treatment (254) 254
animals (223) 223
clinical trials (218) 218
pharmacology & pharmacy (216) 216
therapy (199) 199
antineoplastic combined chemotherapy protocols - adverse effects (189) 189
phase-i/ii trial (189) 189
phase i/ii trial (180) 180
hematology (178) 178
radiology, nuclear medicine & medical imaging (177) 177
research (175) 175
tumors (175) 175
immunotherapy (173) 173
aged, 80 and over (171) 171
antineoplastic agents - therapeutic use (169) 169
toxicity (169) 169
trial (166) 166
combined modality therapy (161) 161
medicine & public health (160) 160
clinical trials as topic (156) 156
neoplasm staging (153) 153
cisplatin (148) 148
i/ii (146) 146
disease-free survival (145) 145
radiation-therapy (143) 143
survival rate (141) 141
hematology, oncology and palliative medicine (140) 140
immunology (140) 140
carcinoma (139) 139
drug administration schedule (136) 136
dose-response relationship, drug (132) 132
medicine, research & experimental (127) 127
analysis (121) 121
survival (119) 119
follow-up studies (117) 117
survival analysis (116) 116
prognosis (115) 115
adolescent (112) 112
surgery (112) 112
cisplatin - administration & dosage (110) 110
combination (110) 110
health aspects (110) 110
radiotherapy dosage (110) 110
maximum tolerated dose (109) 109
metastasis (109) 109
patients (106) 106
lung neoplasms - drug therapy (105) 105
i/ii trial (104) 104
radiation (101) 101
paclitaxel (98) 98
antineoplastic combined chemotherapy protocols - administration & dosage (97) 97
prospective studies (97) 97
efficacy (95) 95
breast cancer (94) 94
radiation therapy (93) 93
neoplasm metastasis (92) 92
antibodies, monoclonal - therapeutic use (90) 90
child (90) 90
dendritic cells (89) 89
carcinoma, non-small-cell lung - drug therapy (87) 87
carboplatin (86) 86
cell lung-cancer (86) 86
deoxycytidine - analogs & derivatives (86) 86
clinical trials, phase ii as topic (85) 85
phase i (85) 85
antineoplastic agents - administration & dosage (84) 84
paclitaxel - administration & dosage (84) 84
lung neoplasms - pathology (83) 83
clinical trials, phase i as topic (81) 81
drug therapy (81) 81
mice (81) 81
fluorouracil - administration & dosage (80) 80
phase-i-ii (80) 80
phase i-ii (78) 78
medical research (77) 77
neoplasms - drug therapy (77) 77
5-fluorouracil (76) 76
cancer therapies (75) 75
gemcitabine (73) 73
retrospective studies (73) 73
statistics & probability (73) 73
cancer research (72) 72
cell line, tumor (72) 72
deoxycytidine - administration & dosage (71) 71
review (71) 71
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1733) 1733
Japanese (49) 49
French (11) 11
German (6) 6
Polish (2) 2
Spanish (2) 2
Korean (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical cancer research, ISSN 1557-3265, 2010, Volume 16, Issue 10, pp. 2861 - 2871
Journal Article
Journal Article
Current oncology (Toronto), ISSN 1718-7729, 2018, Volume 25, Issue Suppl 1, pp. 59 - S67
.... In the 10 years that have elapsed since the discovery of the ALK gene in a patient with nsclc, several active drugs have moved rapidly from bench to bedside, and multiple others are currently in clinical trials... 
Brigatinib | CNS metastases | Crizotinib | Resistance | Alectinib | NSCLC | ALK inhibitors | Ceritinib | SURVIVAL | OLIGOPROGRESSIVE DISEASE | OPEN-LABEL | ANTITUMOR-ACTIVITY | PHASE I/II | ceritinib | resistance | alectinib | CELL LUNG-CANCER | ANAPLASTIC LYMPHOMA KINASE | brigatinib | crizotinib | ONCOLOGY | BRAIN METASTASES | PROGRESSION-FREE | CRIZOTINIB RESISTANCE | cns metastases | alk inhibitors | nsclc | Review
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 4/2008, Volume 61, Issue 4, pp. 535 - 548
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2014, Volume 32, Issue 23, pp. 2505 - 2511
Purpose We provide a comprehensive review of adaptive phase I clinical trials in oncology that used a statistical model to guide dose escalation to identify the maximum-tolerated dose (MTD... 
I/II TRIAL | SOLID TUMORS | ONCOLOGY | BRAIN-TUMOR CONSORTIUM | CONTINUAL REASSESSMENT METHOD | CANCER | REFRACTORY CNS MALIGNANCIES | FARNESYLTRANSFERASE INHIBITOR LONAFARNIB | RADIATION-THERAPY | ESCALATION | CHILDREN | Dose-Response Relationship, Drug | Clinical Trials, Phase I as Topic - methods | Maximum Tolerated Dose | Antineoplastic Agents - administration & dosage | Humans | Neoplasms - drug therapy | Bios5 | Bios3 | Review | Faze
Journal Article
Biostatistics, ISSN 1465-4644, 04/2016, Volume 17, Issue 2, pp. 249 - 263
Journal Article